Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

Kelley, Robin KateRobin KateKelleySangro, BrunoBrunoSangroHarris, WilliamWilliamHarrisIkeda, MasafumiMasafumiIkedaOkusaka, TakujiTakujiOkusakaKang, Yoon-KooYoon-KooKangQin, ShukuiShukuiQinTai, David W-MDavid W-MTaiLim, Ho YeongHo YeongLimYau, ThomasThomasYauYong, Wei-PengWei-PengYongANN-LII CHENGGasbarrini, AntonioAntonioGasbarriniDamian, SilviaSilviaDamianBruix, JordiJordiBruixBorad, MiteshMiteshBoradBendell, JohannaJohannaBendellKim, Tae-YouTae-YouKimStandifer, NathanNathanStandiferHe, PhilipPhilipHeMakowsky, MalloryMalloryMakowskyNegro, AlejandraAlejandraNegroKudo, MasatoshiMasatoshiKudoAbou-Alfa, Ghassan KGhassan KAbou-Alfa2023-01-122023-01-122021-09-200732-183Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/627192This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unresectable hepatocellular carcinoma (HCC), including a novel regimen featuring a single, priming dose of tremelimumab (ClinicalTrials.gov identifier: NCT02519348).enMETASTATIC MELANOMA; ANTITUMOR-ACTIVITY; RESPONSE CRITERIA; THERAPY; IPILIMUMAB; SURVIVAL; TRIAL; SORAFENIB; NIVOLUMAB; BLOCKADE[SDGs]SDG3Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Studyjournal article10.1200/JCO.20.03555342927922-s2.0-85115016862WOS:000708091800004https://api.elsevier.com/content/abstract/scopus_id/85115016862